<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336266">
  <stage>Registered</stage>
  <submitdate>23/11/2010</submitdate>
  <approvaldate>24/11/2010</approvaldate>
  <actrnumber>ACTRN12610001036000</actrnumber>
  <trial_identification>
    <studytitle>Finding the Genes for Gout: the effect of fructose</studytitle>
    <scientifictitle>The influence of genetic variants on fructose-induced hyperuricaemia</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>NA</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hyperuricaemia</healthcondition>
    <healthcondition>Gout</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A sugar solution of 300kcal/300ml will be administered to all participants.  This solution will contain 80% fructose and 20% glucose (64g fructose and 16g glucose).  Participants will then be observed for three hours.</interventions>
    <comparator>Nil</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in serum urate concentration following a fructose challenge (blood test)</outcome>
      <timepoint>30 minutes, 60 minutes, 120 minutes, and 180 minutes after ingestion</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in fractional excretion of urate to 3 hours following a fructose challenge (blood and urine test)</outcome>
      <timepoint>30 minutes, 60 minutes, 120 minutes, and 180 minutes after ingestion</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Able to provide written informed consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>85</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>a.	History of gout
b.	History of diabetes mellitus
c.	History of fructose intolerance
d.	Diuretic use
e.	Fasting capillary glucose &gt;6mmol/L</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Cross-sectional</duration>
    <selection>Convenience sample</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/08/2011</anticipatedstartdate>
    <actualstartdate>6/10/2011</actualstartdate>
    <anticipatedenddate>29/02/2012</anticipatedenddate>
    <actualenddate>29/02/2012</actualenddate>
    <samplesize>75</samplesize>
    <actualsamplesize>76</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Health Research Council of New Zealand</primarysponsorname>
    <primarysponsoraddress>PO Box 5541, Wellesley Street, Auckland, 1141, New Zealand</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Health Research Council of New Zealand</fundingname>
      <fundingaddress>PO Box 5541, Wellesley Street, Auckland, 1141, New Zealand</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>We have previously identified genetic variation in a urate transporter gene SLC2A9 as a key risk factor for development of gout in those of Maori, Pacific and Caucasian ancestry.  This transporter is also a fructose transporter and in vitro assays have shown that fructose promotes transport of urate via SLC2A9.  These observations are of clinical relevance, as fructose ingestion has been strongly associated with development of hyperuricaemia and gout.  

We wish to extend our initial observations by examining the influence of SLC2A9 genetic variation on fructose-induced hyperuricaemia.  The primary hypothesis is that individuals possessing at least one protective allele at rs11942223 have a lower hyperuricaemic response to a fructose challenge. 

This study involves a fructose challenge test for 75 healthy volunteer control participants.  The fructose challenge test takes approximately 3 hours and involves ingestion of a fructose/glucose drink and serial measurements of blood urate, creatinine and glucose. Blood will also be obtained for genotyping of SLC2A9 variants and other variants associated with hyperuricaemia</summary>
    <trialwebsite />
    <publication>http://ard.bmj.com/content/72/11/1868.long
http://ard.bmj.com/content/73/1/313.long</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Multiregion Ethics Committee</ethicname>
      <ethicaddress>PO Box 5013
Wellington</ethicaddress>
      <ethicapprovaldate>27/07/2010</ethicapprovaldate>
      <hrec>MEC/05/10/130</hrec>
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Nicola Dalbeth</name>
      <address>Bone and Joint Research Group
Department of Medicine
Faculty of Medical and Health Sciences
University of Auckland
Park Rd , Grafton, Auckland 1023</address>
      <phone>+64 (0) 9 3737999 x82568</phone>
      <fax />
      <email>n.dalbeth@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Nicola Dalbeth</name>
      <address>Bone and Joint Research Group
Department of Medicine
Faculty of Medical and Health Sciences
University of Auckland
Park Rd , Grafton, Auckland 1023</address>
      <phone>+64 (0) 9 3737999 x82568</phone>
      <fax />
      <email>n.dalbeth@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Nicola Dalbeth </name>
      <address>Room 502-201D
Bone and Joint Research Group
Department of Medicine
Faculty of Medical and Health Sciences
University of Auckland
85 Park Rd, Grafton, Auckland 1023
</address>
      <phone>+64 (0) 9 3737999 x82568</phone>
      <fax />
      <email>n.dalbeth@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>